100 related articles for article (PubMed ID: 12783204)
1. Peptides designed from molecular modeling studies of the ras-p21 protein induce phenotypic reversion of a pancreatic carcinoma cell line but have no effect on normal pancreatic acinar cell growth.
Kanovsky M; Michl J; Botzolaki G; Morin J; Kovac C; Chung DL; Chie L; Friedman FK; Pincus MR
Cancer Chemother Pharmacol; 2003 Sep; 52(3):202-8. PubMed ID: 12783204
[TBL] [Abstract][Full Text] [Related]
2. Two peptides derived from ras-p21 induce either phenotypic reversion or tumor cell necrosis of ras-transformed human cancer cells.
Adler V; Bowne W; Kamran I; Michl J; Friedman FK; Chin E; Zenilman M; Pincus MR
Cancer Chemother Pharmacol; 2008 Aug; 62(3):491-8. PubMed ID: 18066549
[TBL] [Abstract][Full Text] [Related]
3. A protein kinase C inhibitor induces phenotypic reversion of ras-transformed pancreatic cancer cells and cooperatively blocks tumor cell proliferation with an anti- ras peptide.
Way D; Smith S; Sivendran S; Chie L; Kanovsky M; Brandt-Rauf PW; Chung DL; Michl J; Pincus MR
Cancer Chemother Pharmacol; 2002 Jun; 49(6):429-37. PubMed ID: 12107546
[TBL] [Abstract][Full Text] [Related]
4. A peptide from a ras effector-domain blocks ras-dependent cardiac hypertrophy in myocytes.
Deng L; Boujdir M; Tremontano A; Pincus MR; El-Sherif N
Ann Clin Lab Sci; 2009; 39(4):351-60. PubMed ID: 19880762
[TBL] [Abstract][Full Text] [Related]
5. Site-specific phosphorylation of raf in cells containing oncogenic ras-p21 is likely mediated by jun-N-terminal kinase.
Adler V; Bowne W; Michl J; Sookraj KA; Ikram K; Pestka S; Izotova L; Zenilman M; Friedman FK; Qu Y; Pincus MR
Ann Clin Lab Sci; 2008; 38(1):47-56. PubMed ID: 18316782
[TBL] [Abstract][Full Text] [Related]
6. Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation.
Aoki K; Yoshida T; Matsumoto N; Ide H; Sugimura T; Terada M
Mol Carcinog; 1997 Oct; 20(2):251-8. PubMed ID: 9364215
[TBL] [Abstract][Full Text] [Related]
7. The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells.
Bowne WB; Sookraj KA; Vishnevetsky M; Adler V; Sarafraz-Yazdi E; Lou S; Koenke J; Shteyler V; Ikram K; Harding M; Bluth MH; Ng M; Brandt-Rauf PW; Hannan R; Bradu S; Zenilman ME; Michl J; Pincus MR
Ann Surg Oncol; 2008 Dec; 15(12):3588-600. PubMed ID: 18931881
[TBL] [Abstract][Full Text] [Related]
8. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
[TBL] [Abstract][Full Text] [Related]
9. Anti-cancer peptides from ras-p21 and p53 proteins.
Pincus MR; Fenelus M; Sarafraz-Yazdi E; Adler V; Bowne W; Michl J
Curr Pharm Des; 2011; 17(25):2677-98. PubMed ID: 21728981
[TBL] [Abstract][Full Text] [Related]
10. PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo.
Michl J; Scharf B; Schmidt A; Huynh C; Hannan R; von Gizycki H; Friedman FK; Brandt-Rauf P; Fine RL; Pincus MR
Int J Cancer; 2006 Oct; 119(7):1577-85. PubMed ID: 16688716
[TBL] [Abstract][Full Text] [Related]
11. Development of new anti-cancer peptides from conformational energy analysis of the oncogenic ras-p21 protein and its complexes with target proteins.
Pincus MR
Front Biosci; 2004 Sep; 9():3486-509. PubMed ID: 15353372
[TBL] [Abstract][Full Text] [Related]
12. Novel peptides from the RAS-p21 and p53 proteins for the treatment of cancer.
Bowne WB; Michl J; Bluth MH; Zenilman ME; Pincus MR
Cancer Ther; 2007; 5B():331-344. PubMed ID: 18007958
[TBL] [Abstract][Full Text] [Related]
13. Suppression of pancreatic cancer by the dominant negative ras mutant, N116Y.
Shichinohe T; Senmaru N; Furuuchi K; Ogiso Y; Ishikura H; Yoshiki T; Takahashi T; Kato H; Kuzumaki N
J Surg Res; 1996 Dec; 66(2):125-30. PubMed ID: 9024823
[TBL] [Abstract][Full Text] [Related]
14. Plasmid expression of a peptide that selectively blocks oncogenic ras-p21-induced oocyte maturation.
Kovac C; Clie L; Morin J; Friedman FK; Robinson R; Chung DL; Kanovsky M; Flom J; Brandt-Rauf PW; Yamaizumi Z; Michl J; Pincus MR
Cancer Chemother Pharmacol; 2001 Jul; 48(1):9-14. PubMed ID: 11488531
[TBL] [Abstract][Full Text] [Related]
15. Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis.
Lebedeva IV; Su ZZ; Sarkar D; Gopalkrishnan RV; Waxman S; Yacoub A; Dent P; Fisher PB
Oncogene; 2005 Jan; 24(4):585-96. PubMed ID: 15580305
[TBL] [Abstract][Full Text] [Related]
16. Effector peptides from glutathione-S-transferase-pi affect the activation of jun by jun-N-terminal kinase.
Adler V; Pincus MR
Ann Clin Lab Sci; 2004; 34(1):35-46. PubMed ID: 15038666
[TBL] [Abstract][Full Text] [Related]
17. In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis.
Qian J; Niu J; Li M; Chiao PJ; Tsao MS
Cancer Res; 2005 Jun; 65(12):5045-53. PubMed ID: 15958547
[TBL] [Abstract][Full Text] [Related]
18. Expression profiling of the influence of RAS mutants on the TGFB1-induced phenotype of the pancreatic cancer cell line PANC-1.
Fensterer H; Giehl K; Buchholz M; Ellenrieder V; Buck A; Kestler HA; Adler G; Gierschik P; Gress TM
Genes Chromosomes Cancer; 2004 Mar; 39(3):224-35. PubMed ID: 14732924
[TBL] [Abstract][Full Text] [Related]
19. Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer.
Kubuschok B; Neumann F; Breit R; Sester M; Schormann C; Wagner C; Sester U; Hartmann F; Wagner M; Remberger K; Schilling M; Pfreundschuh M
Clin Cancer Res; 2006 Feb; 12(4):1365-72. PubMed ID: 16489095
[TBL] [Abstract][Full Text] [Related]
20. Functional interactions of Raf and MEK with Jun-N-terminal kinase (JNK) result in a positive feedback loop on the oncogenic Ras signaling pathway.
Adler V; Qu Y; Smith SJ; Izotova L; Pestka S; Kung HF; Lin M; Friedman FK; Chie L; Chung D; Boutjdir M; Pincus MR
Biochemistry; 2005 Aug; 44(32):10784-95. PubMed ID: 16086581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
